OBJECTIVE: The authors examined trends in the use of second-generation antipsychotics for treatment of bipolar disorder before and after the U.S. Food and Drug Administration's approval in 2000 of olanzapine for use in treating acute manic episodes of bipolar disorder. METHODS: The IMS Health National Disease and Therapeutic Index was used to derive monthly patient treatment visits between January 1998 and December 2009 by individuals 18 and older with a diagnosis of bipolar disorder who were treated with one or more pharmacotherapies. RESULTS: The percentage of treatment visits in which a second-generation antipsychotic was prescribed increased from 18% in 1998 to 49% in 2009. Use of mood stabilizers and first-generation antipsychotics declined substantially. In the 12 months after approval of olanzapine for bipolar disorder, its use increased by 92%, and use of other second-generation antipsychotics increased by 42%. CONCLUSIONS: Second-generation antipsychotics are increasingly used for bipolar disorder, and their effectiveness compared with therapeutic alternatives merits further research.
OBJECTIVE: The authors examined trends in the use of second-generation antipsychotics for treatment of bipolar disorder before and after the U.S. Food and Drug Administration's approval in 2000 of olanzapine for use in treating acute manic episodes of bipolar disorder. METHODS: The IMS Health National Disease and Therapeutic Index was used to derive monthly patient treatment visits between January 1998 and December 2009 by individuals 18 and older with a diagnosis of bipolar disorder who were treated with one or more pharmacotherapies. RESULTS: The percentage of treatment visits in which a second-generation antipsychotic was prescribed increased from 18% in 1998 to 49% in 2009. Use of mood stabilizers and first-generation antipsychotics declined substantially. In the 12 months after approval of olanzapine for bipolar disorder, its use increased by 92%, and use of other second-generation antipsychotics increased by 42%. CONCLUSIONS: Second-generation antipsychotics are increasingly used for bipolar disorder, and their effectiveness compared with therapeutic alternatives merits further research.
Authors: Joseph R Calabrese; Paul E Keck; Wayne Macfadden; Margaret Minkwitz; Terence A Ketter; Richard H Weisler; Andrew J Cutler; Robin McCoy; Ellis Wilson; Jamie Mullen Journal: Am J Psychiatry Date: 2005-07 Impact factor: 18.112
Authors: Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis Journal: Arch Gen Psychiatry Date: 2006-10
Authors: Ruud van Winkel; Marc De Hert; Dominique Van Eyck; Linda Hanssens; Martien Wampers; Andre Scheen; Joseph Peuskens Journal: Bipolar Disord Date: 2008-03 Impact factor: 6.744
Authors: Linmarie Sikich; Jean A Frazier; Jon McClellan; Robert L Findling; Benedetto Vitiello; Louise Ritz; Denisse Ambler; Madeline Puglia; Ann E Maloney; Emily Michael; Sandra De Jong; Karen Slifka; Nancy Noyes; Stefanie Hlastala; Leslie Pierson; Nora K McNamara; Denise Delporto-Bedoya; Robert Anderson; Robert M Hamer; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2008-09-15 Impact factor: 18.112
Authors: Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs Journal: World Psychiatry Date: 2017-06 Impact factor: 49.548
Authors: Davy Vancampfort; Brendon Stubbs; Alex J Mitchell; Marc De Hert; Martien Wampers; Philip B Ward; Simon Rosenbaum; Christoph U Correll Journal: World Psychiatry Date: 2015-10 Impact factor: 49.548
Authors: Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs Journal: World Psychiatry Date: 2016-06 Impact factor: 49.548
Authors: Christopher J Miller; Mingfei Li; Robert B Penfold; Austin F Lee; Eric G Smith; David N Osser; Laura Bajor; Mark S Bauer Journal: BMC Psychiatry Date: 2014-11-30 Impact factor: 3.630
Authors: Alejandro Szmulewicz; Cecilia Samamé; Pablo Caravotta; Diego J Martino; Ana Igoa; Diego Hidalgo-Mazzei; Francesc Colom; Sergio A Strejilevich Journal: Int J Bipolar Disord Date: 2016-02-16